rss
Br J Ophthalmol 2008;92:866-867
  • Mailbox
    • PostScript

Therapeutic anti-VEGF in age-related macular degeneration: Ranibizumab and Bevacizumab controversy

  1. S Flores Moreno1,
  2. J Bautista Paloma2
  1. 1
    Andalusian Agency for Health Technology Assessment, Seville, Spain
  2. 2
    Virgen del Rocío Hospital, Seville, Spain
  1. Dr S Flores Moreno, Andalusian Agency for Health Technology Assessment, Zafra street, n°1 Seville, 41006 Spain; sandra.flores.sspa{at}juntadeandalucia.es
  • Accepted 4 March 2008

The use of intravitreal Bevacizumab had been considered a first-line therapy in age-related macular degeneration (AMD) treatment until 2 years ago, despite the fact that there were no clinical trials backing it and that Bevacizumab was not created for that purpose. Consequently, Genentech modified the molecule of Bevacizumab, without affecting the basis of its efficacy but with the specific aim of treating this pathology, and so the new drug Ranibizumab was developed. However, no indirect comparisons have revealed any significant differences between both treatments in efficacy.1–3

The …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.